We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+34.33%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.17B
AUM Growth
+$193M
(+4.9%)
Cap. Flow
-$193M
Cap. Flow
% of AUM
-4.62%
Top 10 Holdings %
Top 10 Hldgs %
41.32%
Holding
120
New
16
Increased
14
Reduced
24
Closed
15
Top Buys
| 1 |
Danaher
DHR
|
+$52.4M |
| 2 |
Cigna
CI
|
+$48.2M |
| 3 |
United Therapeutics
UTHR
|
+$38.6M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$29.4M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$28.9M |
Top Sells
| 1 |
UnitedHealth
UNH
|
+$105M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$93.6M |
| 3 |
Tenet Healthcare
THC
|
+$81.8M |
| 4 |
Boston Scientific
BSX
|
+$39.8M |
| 5 |
Cytokinetics
CYTK
|
+$35.6M |
Sector Composition
| 1 | Healthcare | 99.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Thermo Fisher Scientific
TMO
$199B
| $22.6M | 0.54% |
46,500
| – | – |
|
52
Rhythm Pharmaceuticals
RYTM
$7.52B
| $21.7M | 0.52% |
215,152
-33,360
| -13% | -$3.1M |
|
53
Krystal Biotech
KRYS
$10.2B
| $18.1M | 0.44% |
102,745
+93,545
| +1,017% | +$14M |
|
54
Forte Biosciences
FBRX
$889M
| $18M | 0.43% |
1,196,955
| – | – |
|
55
Avalo Therapeutics
AVTX
$979M
| $17.1M | 0.41% |
1,349,300
+382,300
| +40% | +$3.29M |
|
56
Xenon Pharmaceuticals
XENE
$6.52B
| $16.8M | 0.4% |
419,600
-528,277
| -56% | -$18.6M |
|
|
CARL
57
Carlsmed
CARL
$298M
| $16.8M | 0.4% |
+1,252,600
| New | +$17.1M |
|
58
Keros Therapeutics
KROS
$211M
| $16.1M | 0.39% |
1,018,734
| – | – |
|
59
Prelude Therapeutics
PRLD
$355M
| $15.7M | 0.38% |
10,909,256
| – | – |
|
60
Shattuck Labs
STTK
$610M
| $15.1M | 0.36% |
+6,306,127
| New | +$7.72M |
|
61
Corbus Pharmaceuticals
CRBP
$165M
| $14.8M | 0.36% |
1,172,287
| – | – |
|
62
UroGen Pharma
URGN
$1.95B
| $13.7M | 0.33% |
689,000
+210,600
| +44% | +$3.78M |
|
63
Vir Biotechnology
VIR
$1.61B
| $13.6M | 0.33% |
2,380,715
| – | – |
|
|
FOLD
64
DELISTED
Amicus Therapeutics
FOLD
| $13M | 0.31% |
1,645,400
-640,000
| -28% | -$4.55M |
|
65
Tarsus Pharmaceuticals
TARS
$2.43B
| $11.8M | 0.28% |
197,900
| – | – |
|
66
C4 Therapeutics
CCCC
$415M
| $11.6M | 0.28% |
5,235,146
-1,595,154
| -23% | -$3.83M |
|
67
Cullinan Oncology
CGEM
$1.08B
| $11.4M | 0.27% |
1,923,855
| – | – |
|
68
VistaGen Therapeutics
VTGN
$10M
| $10.9M | 0.26% |
+3,060,000
| New | +$9.14M |
|
69
Amylyx Pharmaceuticals
AMLX
$1.97B
| $10.2M | 0.24% |
750,600
+437,400
| +140% | +$4.12M |
|
70
Adicet Bio
ACET
$80.8M
| $9.27M | 0.22% |
715,446
| – | – |
|
71
PMV Pharmaceuticals
PMVP
$74.7M
| $8.37M | 0.2% |
5,975,291
-500,000
| -8% | -$692K |
|
|
WHWK
72
Whitehawk Therapeutics
WHWK
$190M
| $7.92M | 0.19% |
4,166,000
| – | – |
|
73
Verastem
VSTM
$488M
| $7.84M | 0.19% |
+887,561
| New | +$6.61M |
|
74
BrightSpring Health Services
BTSG
$13.5B
| $7.8M | 0.19% |
+263,800
| New | +$6.13M |
|
|
ALMS
75
Alumis Inc
ALMS
$3.54B
| $7.69M | 0.18% |
1,926,423
| – | – |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM